| http://purl.uniprot.org/citations/35263569 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/35263569 | http://www.w3.org/2000/01/rdf-schema#comment | "Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8+ T cells. Although PD-1 and TIGIT are thought to regulate different costimulatory receptors (CD28 and CD226), effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. CD226 expression associated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-PD-L1 antibody atezolizumab. CD226 and CD28 were co-expressed on NSCLC infiltrating CD8+ T cells poised for expansion. Mechanistically, PD-1 inhibited phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD); TIGIT's ICD was dispensable, with TIGIT restricting CD226 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of CD226 signaling, and optimal anti-tumor CD8+ T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.immuni.2022.02.005"xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Xu X."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Takahashi C."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Wu T.D."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Mellman I."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Bennett E.J."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Mittman S."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Hui E."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Grogan J.L."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Comps-Agrar L."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Fulzele A."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Chiang E.Y."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "O'Gorman W.E."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Cubas R."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Banta K.L."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Chitre A.S."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/author | "Au-Yeung A."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/date | "2022"xsd:gYear |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/name | "Immunity"xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/pages | "512-526.e9"xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/title | "Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8pisup>+pi/sup> T cell responses."xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://purl.uniprot.org/core/volume | "55"xsd:string |
| http://purl.uniprot.org/citations/35263569 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/35263569 |